Cingulate Inc. (CING)
| Market Cap | 63.34M +278.1% |
| Revenue (ttm) | n/a |
| Net Income | -22.45M |
| EPS | -4.44 |
| Shares Out | 12.25M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 122,703 |
| Open | 5.26 |
| Previous Close | 5.23 |
| Day's Range | 5.02 - 5.30 |
| 52-Week Range | 3.20 - 11.89 |
| Beta | -0.81 |
| Analysts | Strong Buy |
| Price Target | 34.50 (+567.31%) |
| Earnings Date | May 19, 2026 |
About CING
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company’s lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for CING stock is "Strong Buy." The 12-month stock price target is $34.5, which is an increase of 567.31% from the latest price.
News
Six new option listings on April 22nd
New option listings for April 22nd include SPDR Bridgewater All Weather ETF (ALLW), Cingulate Inc (CING), Tema ETF Trust (NASA), Eagle Nuclear Energy Corp (NUCL), Versigent PLC (VGNT), and Xanadu
Cingulate files to sell 4.21M shares of common stock for holders
17:27 EDT Cingulate (CING) files to sell 4.21M shares of common stock for holders
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 4Q25
Dallas, Texas--(Newsfile Corp. - April 6, 2026) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's 4Q25 update continues t...
Cingulate price target lowered to $14 from $16 at Roth Capital
Roth Capital lowered the firm’s price target on Cingulate (CING) to $14 from $16 and keeps a Buy rating on the shares. The company’s new drug application for CTx-1301 in
Cingulate files to sell 3.5M shares of common stock for holders
07:40 EDT Cingulate (CING) files to sell 3.5M shares of common stock for holders
Cingulate announces U.S. patent notice of allowance
On Tuesday, March 17th, 2026, the United States Patent and Trademark Office issued a Notice of Allowance for a patent application covering Cingulate’s (CING) lead ADHD candidate, CTx-1301, indicating ...
Cingulate reports Q4 net loss $6.3M vs. $6.2M last year
Cingulate (CING) CEO Shane Schaffer stated, “Cingulate delivered on key inflection points throughout 2025 and this continues into 2026. Cingulate is proud to announce that CTx-1301 has strengthened it...
Cingulate sees cash runway into late 4Q26
As of December 31, 2025, Cingulate (CING) had approximately $11.0 million in cash and cash equivalents, a $1.3 million decrease from December 31, 2024. The Company expects current cash on
Why did Cingulate stock skyrocket today?
Cingulate Inc (NASDAQ: CING) soared on Monday morning after the US Patent and Trademark Office (USPTO) cleared a key patent application for the firm's “Trimodal, Precision-Time Pulsatile Release Table...
Cingulate files $200M mixed securities shelf
17:10 EST Cingulate (CING) files $200M mixed securities shelf
Cingulate price target lowered to $16 from $17 at Roth Capital
Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Cingulate (CING) to $16 from $17 and keeps a Buy rating on the shares after meeting with its management
Cingulate price target lowered to $16 from $17 at Roth Capital
Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Cingulate (CING) to $16 from $17 and keeps a Buy rating on the shares, with the firm noting it
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 3Q25
Dallas, Texas--(Newsfile Corp. - November 18, 2025) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate's 3Q25 results reflec...
Cingulate reports Q3 net loss ($7.3M) vs ($4.1M) last year
As of September 30, 2025, Cingulate (CING) had approximately $6.1 million in cash and cash equivalents, a $6.1 million decrease from December 31, 2024. The Company expects its cash will
Cingulate names Downey as CCO to lead launch prep for CTx-1301
Cingulate (CING) announced the appointment of Bryan Downey as Chief Commercial Officer, CCO, following the U.S. Food and Drug Administration’s, FDA, acceptance of Cingulate’s New Drug Application, NDA...
Cingulate presents Phase 3 results for CTx-1301, met primary endpoint
Cingulate (CING) announced that the positive Phase 3 results from its pivotal trial of CTx-1301 in pediatric ADHD, were recently presented by Ann Childress, M.D., at the AACAP Annual Meeting
Cingulate's Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
Presentation by ADHD expert Dr. Ann Childress to highlight Phase 3 findings supporting the potential for true, entire active-day symptom control Presentation by ADHD expert Dr. Ann Childress to highli...
Cingulate price target raised to $17 from $10 at Roth Capital
Roth Capital raised the firm’s price target on Cingulate (CING) to $17 from $10 and keeps a Buy rating on the shares. The FDA’s acceptance of Cingulate’s NDA package suggests
Cingulate announces FDA accepted for review the NDA for CTx-1301
Cingulate (CING) announced that the U.S. Food and Drug Administration, FDA, has accepted for review the New Drug Application, NDA, for CTx-1301, the company’s lead candidate for the treatment of
Cingulate secures exclusive manufacturing partnership with Bend Bio Sciences
Cingulate (CING) announced it has entered into a commercial supply agreement with Bend Bio Sciences for the manufacturing of CTx-1301, the company’s lead asset for the treatment of attention deficit/h...
Cingulate Secures Exclusive Manufacturing Partnership with Bend Bio Sciences to Support Future Commercialization of Next Generation ADHD Treatment
Strategic Commercial Supply Agreement Positions Lead Asset CTx-1301 for Launch Pending FDA Approval Strategic Commercial Supply Agreement Positions Lead Asset CTx-1301 for Launch Pending FDA Approval
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 2Q25
Dallas, Texas--(Newsfile Corp. - August 21, 2025) - Cingulate Inc. (NASDAQ: CING): Stonegate Capital Partners updates their coverage on Cingulate Inc. (NASDAQ: CING). Cingulate reported 2Q25 results t...
Cingulate price target lowered to $10 from $11 at Roth Capital
Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on Cingulate (CING) to $10 from $11 but keeps a Buy rating on the shares. The firm’s post-Q2 call with
Cingulate reports Q2 net loss ($4.8M) vs ($3.2M) last year
As of June 30, 2025, Cingulate (CING) had approximately $8.9 million in cash and cash equivalents, a $3.3 million decrease from December 31, 2024. The Company expects its cash will
Cingulate Inc. Reports Second Quarter 2025 Financial Results and Provides Recent Highlights
Submitted New Drug Application (NDA) to the FDA for lead asset CTx-1301 Anticipate FDA Decision in Q4 2025 regarding NDA Acceptance with Potential PDUFA Date in Mid-2026